<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39420385</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-6511</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>BMC pharmacology &amp; toxicology</Title><ISOAbbreviation>BMC Pharmacol Toxicol</ISOAbbreviation></Journal><ArticleTitle>Effect of Tenofovir Alafenamide Fumarate on the outcomes of hospitalized COVID-19 patients: a prospective, block-balanced, open-label, randomized controlled trial.</ArticleTitle><Pagination><StartPage>78</StartPage><MedlinePgn>78</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">78</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40360-024-00781-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The global effort to cure COVID-19 is still ongoing. Thus, a prospective, block-balanced, open-label, randomized controlled trial was conducted to evaluate how Tenofovir Alafenamide Fumarate affects hospitalized COVID-19 patients' outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The intervention and control groups of 60 hospitalized COVID-19 patients were randomly allocated. Along with normal medication, the intervention group received 25 mg of tenofovir orally daily for seven days. The control group got normal therapy, including remdesivir and corticosteroids. ICU hospitalization duration, laboratory data, fever, dyspnea, arterial blood oxygen saturation with and without an oxygen face mask, mechanical ventilation, and mortality were the outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty of 236 eligible patients between September 2020 and February 2021 were enrolled. The intervention group had a mean age (±SD) of 61.33 (±13.09) years and the control group 60.03 (±18.03). Sixteen (53.3%) intervention patients and 15 (50.0%) control patients were males. The intervention group had fewer mechanical ventilation and ICU days. Tenofovir Alafenamide Fumarate did not improve fever, dyspnea, oxygen saturation with or without a face mask or nasal cannula, or laboratory data including WBC, ESR, CRP, AST, ALT, AlkP, total and direct bilirubin, in COVID-19 patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">According to this pilot trial, Tenofovir Alafenamide Fumarate, along with conventional treatment, significantly reduced mechanical ventilation and ICU stay in COVID-19 patients. Further thorough research is necessary to verify this conclusion.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yazdan Pouri</LastName><ForeName>Nazanin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Alimentary Tract Research Center, Clinical Sciences Research Institute, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shokati Eshkiki</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Alimentary Tract Research Center, Clinical Sciences Research Institute, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. zahrashokati@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talebi</LastName><ForeName>Afshin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheraghian</LastName><ForeName>Bahman</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Alimentary Tract Research Center, Clinical Sciences Research Institute, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Epidemiology, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadi</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, School of Medicine, Razi Teaching Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neisi</LastName><ForeName>Niloofar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Alimentary Tract Research Center, Clinical Sciences Research Institute, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shayesteh</LastName><ForeName>Ali Akbar</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Alimentary Tract Research Center, Clinical Sciences Research Institute, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. shayeste-a@ajums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Pharmacol Toxicol</MedlineTA><NlmUniqueID>101590449</NlmUniqueID><ISSNLinking>2050-6511</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>99YXE507IL</RegistryNumber><NameOfSubstance UI="D000068698">Tenofovir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EL9943AG5J</RegistryNumber><NameOfSubstance UI="C442442">tenofovir alafenamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068698" MajorTopicYN="Y">Tenofovir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Corticosteroids</Keyword><Keyword MajorTopicYN="N">Randomized clinical trial</Keyword><Keyword MajorTopicYN="N">Remdesivir</Keyword><Keyword MajorTopicYN="N">Tenofovir</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39420385</ArticleId><ArticleId IdType="pmc">PMC11484439</ArticleId><ArticleId IdType="doi">10.1186/s40360-024-00781-3</ArticleId><ArticleId IdType="pii">10.1186/s40360-024-00781-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis JS, Ferreira D, Denholm JT, Tong SY. Clinical trials for the prevention and treatment of COVID-19: current state of play. Med J Aust. 2020;213(2):86–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361919</ArticleId><ArticleId IdType="pubmed">32594562</ArticleId></ArticleIdList></Reference><Reference><Citation>Rommasi F, Nasiri MJ, Mirsaiedi M. Antiviral drugs proposed for COVID-19: action mechanism and pharmacological data. Eur Rev Med Pharmacol Sci. 2021;25(11):4163–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">34156698</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramesh CS, Babu GR, Basu J, Bhushan I, Booth CM, Chinnaswamy G, et al. Choosing wisely for COVID-19: ten evidence-based recommendations for patients and physicians. Nat Med. 2021;27(8):1324–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">34226738</ArticleId></ArticleIdList></Reference><Reference><Citation>García-Albéniz X, Del Amo J, Polo R, Morales-Asencio JM, Hernán MA. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. Eur J Epidemiol. 2022;37(8):789–96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9360718</ArticleId><ArticleId IdType="pubmed">35943669</ArticleId></ArticleIdList></Reference><Reference><Citation>Naggie S, Milstone A, Castro M, Collins SP, Lakshmi S, Anderson DJ, et al. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker exposure response and outcomes of Hydroxychloroquine (HERO-HCQ). Int J Infect Dis. 2023;129:40–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9851717</ArticleId><ArticleId IdType="pubmed">36682681</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2020;173(7):536–41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7394316</ArticleId><ArticleId IdType="pubmed">32589451</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Antiretrovirals and risk of COVID-19 diagnosis and hospitalization in HIV-positive persons. Epidemiology. 2020;31(6):e49–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7541717</ArticleId><ArticleId IdType="pubmed">32773469</ArticleId></ArticleIdList></Reference><Reference><Citation>Copertino Jr DC, Casado Lima BC, Duarte RR, Powell TR, Ormsby CE, Wilkin T, et al. Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. J Biomol Struct Dyn. 2022;40(16):7367–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8448789</ArticleId><ArticleId IdType="pubmed">33734021</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanella I, Zizioli D, Castelli F, Quiros-Roldan E. Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection. Pharmaceuticals. 2021;14(5):454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8150375</ArticleId><ArticleId IdType="pubmed">34064831</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state. AIDS Res Hum Retroviruses. 2016;32(10–11):981–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5067852</ArticleId><ArticleId IdType="pubmed">27526873</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):re1124–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483088</ArticleId><ArticleId IdType="pubmed">22158861</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27133890</ArticleId></ArticleIdList></Reference><Reference><Citation>Drosu NC, Edelman ER, Housman DE. Tenofovir prodrugs potently inhibit Epstein–Barr virus lytic DNA replication by targeting the viral DNA polymerase. Proc Natl Acad Sci. 2020;117(22):12368–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275665</ArticleId><ArticleId IdType="pubmed">32409608</ArticleId></ArticleIdList></Reference><Reference><Citation>Clososki GC, Soldi RA, Silva RMd, Guaratini T, Lopes JN, Pereira PR, et al. Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2. J Braz Chem Soc. 2020;31:1552–6.</Citation></Reference><Reference><Citation>Birkus G, Bam RA, Willkom M, Frey CR, Tsai L, Stray KM, et al. Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors. Antimicrob Agents Chemother. 2016;60(1):316–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4704186</ArticleId><ArticleId IdType="pubmed">26503655</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M, Wang Y, Ye J, Da H, Fang S, Chen L. Dynamic changes of T-lymphocyte subsets and the correlations with 89 patients with coronavirus disease 2019 (COVID-19). Ann Transl Med. 2020;8(18).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7576080</ArticleId><ArticleId IdType="pubmed">33240994</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitjà O, Corbacho-Monné M, Ubals M, Tebé C, Peñafiel J, Tobias A, et al. Hydroxychloroquine for early treatment of adults with mild coronavirus disease 2019: a randomized, controlled trial. Clin Infect Dis. 2021;73(11):e4073–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454406</ArticleId><ArticleId IdType="pubmed">32674126</ArticleId></ArticleIdList></Reference><Reference><Citation>Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Inter Med. 2020;173(8):623–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384270</ArticleId><ArticleId IdType="pubmed">32673060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorizate M, Kräusslich H-G. Role of lipids in virus replication. Cold Spring Harb Perspect Biol. 2011;3(10):a004820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179339</ArticleId><ArticleId IdType="pubmed">21628428</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchjorsen J, Risør MW, Søgaard OS, O’Loughlin KL, Chow S, Paludan SR, et al. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr. 2011;57(4):265–75.</Citation><ArticleIdList><ArticleId IdType="pubmed">21471820</ArticleId></ArticleIdList></Reference><Reference><Citation>Zídek Zk, Franková D, Holý A. Activation by 9®[2-(phosphonomethoxy) propyl] adenine of chemokine (RANTES, macrophage inflammatory protein 1α) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1β) production. Antimicrob Agents Chemother. 2001;45(12):3381–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC90841</ArticleId><ArticleId IdType="pubmed">11709312</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg EJ, He G-X, Lee WA. Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids. 2001;20(4–7):1091–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11562963</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitz M, Zolopa A, Ruane P, Squires K, Zhong L, Kearney B, et al. editors. GS-7340 demonstrates greater declines in HIV-1 RNA than tenofovir disoproxil fumarate during 14 days of monotherapy in HIV-1 infected subjects. 18th Conference on Retroviruses and Opportunistic Infections; 2011.</Citation></Reference><Reference><Citation>Guan WJ, Zhong NS. Clinical characteristics of Covid-19 in China. Reply. N Engl J Med. 2020;382(19):1861–2.</Citation><ArticleIdList><ArticleId IdType="pubmed">32220206</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso L, Abella BS, Ferrer R, Kucher N, Sunde K, Taccone FS. Fever management in COVID-19 patients. Minerva Anestesiol. 2021;87(1):1–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">33231411</ArticleId></ArticleIdList></Reference><Reference><Citation>Shokati Eshkiki Z, Shahriari A, Seyedtabib M, Torabizadeh M, Assarehzadegan MA, Nashibi R, Khosravi M, Neisi N, Mard SA, Shayesteh AA. Innate and adaptive immunity imbalance with severe COVID-19 pneumonia in children and adults. Front Pediatr. 2021;9:736013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8714948</ArticleId><ArticleId IdType="pubmed">34976886</ArticleId></ArticleIdList></Reference><Reference><Citation>Levitan RM. Pulse oximetry as a biomarker for early identification and hospitalization of COVID-19 pneumonia. Acad Emerg Med. 2020;27(8):785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323007</ArticleId><ArticleId IdType="pubmed">32779867</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Statpearls [internet]. 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Kow CS, Ramachandram DS, Hasan SS. The use of tenofovir in patients with COVID-19. HIV Med. 2022;23(7):807–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">35023263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateos-Muñoz B, Buti M, Vázquez IF, Conde MH, Bernal-Monterde V, Díaz-Fontenla F, et al. Tenofovir disoproxil fumarate reduces the severity of COVID-19 in patients with chronic hepatitis B. Dig Dis Sci. 2023:1–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9897881</ArticleId><ArticleId IdType="pubmed">36737575</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo R, García-Albéniz X, Terán C, Morales M, Rial-Crestelo D, Garcinuño MA, et al. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers. Clin Microbiol Infect. 2023;29(1):85–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352647</ArticleId><ArticleId IdType="pubmed">35940567</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter WP, Sheahan T, Baric R, Holman W, Donovan J, Fang L, et al. Reduction in infectious SARS-CoV-2 in treatment study of COVID-19 with molnupiravir. Top Antivir Med. 2021:304–5.</Citation></Reference><Reference><Citation>DeJong C, Spinelli MA, Okochi H, Gandhi M. Tenofovir-based PrEP for COVID-19: an untapped opportunity? AIDS. 2021;35(9):1509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8243808</ArticleId><ArticleId IdType="pubmed">33710026</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Diaz S, Bateman BT, Straub L, Zhu Y, Mogun H, Fischer M, et al. Safety of tenofovir disoproxil fumarate for pregnant women facing the coronavirus disease 2019 pandemic. Am J Epidemiol. 2021;190(11):2339–49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083317</ArticleId><ArticleId IdType="pubmed">33847737</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>